Media coverage about GenVec (NASDAQ:GNVC) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GenVec earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.5276813641197 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
GenVec (GNVC) traded up 0.000% on Monday, reaching $7.193. The stock’s 50 day moving average price is $6.74 and its 200-day moving average price is $5.80. GenVec has a 12-month low of $0.27 and a 12-month high of $10.44.
GenVec Company Profile
GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.
Receive News & Ratings for GenVec Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc and related companies with MarketBeat.com's FREE daily email newsletter.
